Evolus Sees Toxin Market Stabilizing, Evolysse Gaining Traction, Raises 2028 Revenue Targets at Leerink Conference

Evolus sees signs of stabilization and improvement in the US botulinum toxin market, with executives citing a slowdown in the fourth quarter and first quarter of last year. The company is optimistic about the market's recovery, expecting low-single-digit growth in 2024 and mid-single-digit growth in 2027 and 2028. Evolus' fillers market is lagging behind, but the company is emphasizing "injectable HA" messaging to address consumer concerns about overfilled faces and promote natural-looking outcomes.